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Introduction
There is significant interest in developing means to increase the effectiveness of chemotherapeutic agents used for the treatment of acute myeloid leukemia (AML).
Although chemotherapy results in significant remission rates, there are profound associated toxicities and, even after obtaining complete remission, most patient relapse and die (Büchner et al., 2006; Farag et al., 2005) . AML results from mutations of different groups of genes that control differentiation, proliferation/survival and differentiation/apoptosis (Gilliland and Tallman; . Various mutations lead to aberrant activation of cell survival pathways including the mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) pathways (Bhaskar and Hay, 2007; Martelli et al., 2009; Altman and Platanias, 2008; Platanias, 2003) . As the disease continues to have a very poor prognosis, novel therapeutic approaches are desperately needed to increase the effectiveness of current treatment strategies that traditionally include various chemotherapeutic regimens (Büchner et al., 2006; Farag et al., 2005) .
MAPK pathways play important roles in the regulation of key cellular functions, including control of gene transcription, cell proliferation, and survival. There are three major families of MAP kinases: p38 MAP kinase, the extracellular signal-regulated kinase (Erk), and the c-Jun NH 2 -terminal kinase (JNK) (Platanias, 2005; Raman et al., 2007) . Among other things, MAP kinases play an important functional role in the regulation of normal and malignant hematopoiesis by growth factors and cytokines (Platanias, 2003) . Mnk1 and the related Mnk2 kinases are known downstream effectors of p38 and ERK, and once activated, they phosphorylate the cap binding eukaryotic MOL 64642 5 initiation factor 4E (eIF4E) in response to mitogens and stress signals (Fukunaga and Hunter, 1997; Waskiewicz et al., 1997; Scheper et al., 2001; Waskiewicz et al., 1999) .
As Mnks regulate phosphorylation of eIF4E, a key element of the cap-binding complex, their function complements the mTOR pathway in promoting cap-dependent mRNA translation and malignant cell growth. Although extensive work has been focused in targeting mTOR (Bhaskar and Hay, 2007) , there have been no substantial clinicaltranslational efforts to target Mnk kinases for the treatment of malignancies. In previous work we had demonstrated that Mnk kinases negatively regulate the generation of arsenic trioxide (As 2 O 3 )-induced apoptosis and that antileukemic effects in response to As 2 O 3 can be enhanced by pharmacological inhibition of Mnk (Dolniak et al., 2008) . Although As 2 O 3 is a unique antileukemic agent and induces responses to a large extent via generation of reactive oxygen species (ROS) (Platanias, 2009 ), these findings have raised the possibility that negative feedback regulatory mechanisms involving Mnk kinases may account for development of leukemic cell resistance in response to chemotherapeutic drugs and other antileukemic agents.
Cytarabine (Ara-C) is among the most effective chemotherapeutic drugs for the treatment of AML and has been the key agent used in the treatment of AML for many years (Herzig et al., 1985) . It is a pyrimidine analog that acts as an anti-metabolite and its major use in oncology is in the treatment of AML both at diagnosis and relapse (van Prooijen et al., 1997) . In the present study, we determined the effects of cytarabine on the activation of the Mnk/eIF4E pathway. Our data demonstrate that Mnk is phosphorylated/activated by low-doses of cytarabine and that such phosphorylation leads to downstream activation of eIF4E. Pharmacological or molecular targeting of Mnk in 
Results
In initial studies we sought to determine whether treatment of acute leukemia cells with cytarabine results in activation of Mnk. U937 cells ( Mnk1/2+/+ or Mnk1/2-/-MEFs were treated with cytarabine and eIF4E phosphorylation on Ser209 was assessed. As shown in Fig. 2A , cytarabine-induced phosphorylation of eIF4E on Ser209 was completely abrogated in the absence of Mnk1/Mnk2 ( Fig. 2A) .
Importantly, cytarabine-induced apoptosis was greatly enhanced in such cells ( However, such knockdown strongly enhanced the inhibition of CFU-L formation in response to cytarabine (Fig. 3B ).
This article has not been copyedited and formatted. The final version may differ from this version. Altogether, our studies with cell lines provided strong evidence that activation of the Mnk/eIF4E pathway abrogates chemotherapy-induced apoptosis and generation of antileukemic responses. To determine the functional relevance of this pathway in a more physiologically relevant system, experiments were performed using primary leukemic samples from AML patients. Increasing concentrations of cytarabine resulted in a dosedependent suppression of primitive CFU-L progenitors from AML patients ( Fig 4A) .
Very low doses of cytarabine (0.08 ng/mL), or CGP57380 alone each had minimal effects on leukemic progenitor colony formation ( Fig. 4B ). However, the combination of cytarabine with CGP57380 resulted in potent antileukemic effects, far greater than each agent alone, paired p value = 0.0025 for cytarabine plus CGP57380 versus cytarabine alone, and paired p value = 0.033 for cytarabine plus CGP57380 versus CGP57380 alone (Fig. 4B ).
In previous studies we had demonstrated that targeting of the mTOR pathway enhances the suppressive effects of arsenic trioxide on primary leukemic progenitors from AML patients (Altman et al., 2008) . As both the mTOR and Mnk/eIF4E pathways converge at the level of eIF4E, we sought to determine whether combined targeting of mTOR and Mnk results in enhanced antileukemic effects. In experiments in which the effects of rapamycin on eIF4E phosphorylation on Ser209 were assessed in leukemia cells, we found rapamycin-dependent eIF4E phosphorylation on Ser209 (Fig. 5A ),
suggesting that Mnk kinases are activated in a negative-feedback manner during targeted inhibition of the mTOR pathway. On the other hand, and as expected, treatment of cells with rapamycin inhibited phosphorylation of the p70 S6K (Fig. 5B) . When the effects of dual mTOR and Mnk pharmacological inhibition on CFU-L colony formation derived This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Although the mechanisms by which various chemotherapeutic agents induce cytotoxic effects and apoptosis of malignant cells have been extensively studied, very little is known on negative feedback signaling pathways that are activated as "defense"
mechanisms by malignant cells in response to cytotoxic agents. In previous work we had established that the p38 MAPK and its upstream effectors, Mkk3 and Mkk6, are activated in a negative feedback regulatory manner during treatment of leukemia cells with arsenic trioxide (Giafis et al., 2006; Verma et al., 2002) . Such engagement of the p38 MAPK pathway appears to exhibit negative effects on arsenic-inducible apoptosis and generation of antileukemic responses (Giafis et al., 2006; Verma et al., 2002) .
Similarly, others have shown that the p38 MAPK counteracts induction of pro-apoptotic responses in multiple myeloma cells (Wen et al., 2008) . , 1997) . It is also possible that generation of reactive oxygen species (ROS) is involved in the process, but this remains to be directly examined in future studies.
There is extensive previous evidence that eIF4E has oncogenic activity (Wendel et al., 2004) , while there is an absolute requirement for Mnk-mediated Ser209 phosphorylation for eIF4E's oncogenic action (Wendel et al., 2007) . 
